Accelerating Drug Development Along the Entire Lifecycle distills how to keep discovery, preclinical and clinical bioanalysis in lockstep so decisions land on schedule.
What’s inside:
- Where programs stall and why: Slow CRO TATs, vendor handoffs that force method redevelopment and validation/documentation gaps that trigger QA re-review.
- Phase-aligned LC–MS/MS: Build methods that anticipate GLP/GCP and ICH M10 requirements, with microsampling options and integrated bioanalysis to PK handoffs to support Phases 1–3.
- Sponsor perspective: Andy Vick, PhD, BlueWater Biosciences, on the true cost of delay, how LC–MS can accelerate peptide/biologic selection and what “speed with purpose” looks like in practice.
- Practical tools: A phase-readiness checklist, “tips & traps” to avoid rework-prone choices and snapshots showing how months were saved by pivoting to the right analytical strategy.
- Emerging multiplier: How AI-assisted PK reporting and disciplined documentation shrink cycle times without compromising quality.
Who should read it:
Program leads, DMPK/BioA and Clinical Pharmacology teams and operations/QA leaders who need faster, phase-appropriate decisions backed by GLP/GCP-aligned documentation.
You’ll walk away with:
A blueprint to scope, validate and execute bioanalysis that carries forward efficiently—protecting critical milestones from IND through Phase 3 and into lifecycle updates.
Download the report and align your next study to move faster—with confidence.
